CFRX News and Press, ContraFect Corporation From 03/31/21

If you know what penny stocks are, you understand how risk plays a role. But you can’t expect uncapped gain potential from safe investments. The beauty of buying penny stocks, is having the ability to leverage less capital in exchange for a much larger gain percentage. Defined as...

Contrafect (CFRX): Q4 GAAP EPS of -$0.23 beats by $0.08.Cash, cash equivalents and marketable securities of $42.5MPress Release For further details see: Contrafect EPS beats by $0.08

Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research and Development Authority (BARDA) contract award provides up to $86.8 million f...

YONKERS, N.Y., March 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the closing of an underwritten...

Gainers: Moxian (MOXC) +92%.Jiayin Group (JFIN) +82%.Upstart (UPST) +78%.Dunxin Financial (DXF) +62%.Evolving Systems (EVOL) +28%.China Finance Online (JRJC) +25%.Hallmark Financial Services (HALL) +25%.Express (EXPR) +24%.Takung Art (TKAT) +23%.Luokung Technology (LKCO) +23%.L...

Gainers: Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU) +14%, Vericel (VCEL) +14%, Brickell Biotech (BBI) +14%, Infinity Pharmaceuticals (INFI) +13%.Losers: Translate Bio (TBIO) -32%, ContraFect (CFRX) -13%, Lipocine (LPCN...

Translate Bio (TBIO) -26% after Translate Bio’s Cystic Fibrosis therapy fails to improve lung function in Phase 1/2 trial.PhaseBio Pharmaceuticals (PHAS) -14% on equity raise.Broadway Financial (BYFC) -13% after stockholders of Broadway Financial and CFBan...

ContraFect (CFRX) prices offering of 10M shares of common stock at $5.00/share, for gross proceeds of $50M.Underwriters' option to purchase up to an additional 1.5M shares.The offering to close on March 22, 2021.Shares down 14.5% pre-market.Previously (March 17): ContraFect und...

YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritte...

ContraFect (CFRX) trades 8.4% down after hours on commencing an underwritten public offering of shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer actual size, terms have not yet been disclosed.Net proceeds to be used for funding the c...